Multimodal platform for assessing drug distribution and response in clinical trials

Begoña G.C. Lopez, Ishwar N. Kohale, Ziming Du, Ilya Korsunsky, Walid M. Abdelmoula, Yang Dai, Sylwia A. Stopka, Giorgio Gaglia, Elizabeth C. Randall, Michael S. Regan, Sankha S. Basu, Amanda R. Clark, Bianca Maria Marin, Ann C. Mladek, Danielle M. Burgenske, Jeffrey N. Agar, Jeffrey G. Supko, Stuart A. Grossman, Louis B. Nabors, Soumya RaychaudhuriKeith L. Ligon, Patrick Y. Wen, Brian Alexander, Eudocia Q. Lee, Sandro Santagata, Jann Sarkaria, Forest M. White, Nathalie Y.R. Agar

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. METHODS: Patient-derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee1 inhibitor, and tissue drug distribution was measured with MALDI-MSI. Phosphoproteomics was measured in the same tumors to identify biomarkers of drug target engagement and cellular adaptive response. Multiplexed tissue imaging was performed on sister sections to evaluate spatial co-localization of drug and cellular response. The integrated platform was then applied on clinical specimens from glioblastoma patients enrolled in the phase 1 clinical trial. RESULTS: PDX tumors exposed to different doses of adavosertib revealed intra- and inter-tumoral heterogeneity of drug distribution and integration of the heterogeneous drug distribution with phosphoproteomics and multiplexed tissue imaging revealed new markers of molecular response to adavosertib. Analysis of paired clinical specimens from patients enrolled in the phase 1 clinical trial informed the translational potential of the identified biomarkers in studying patient's response to adavosertib. CONCLUSIONS: The multimodal platform identified a signature of drug efficacy and patient-specific adaptive responses applicable to preclinical and clinical drug development. The information generated by the approach may inform mechanisms of success and failure in future early phase clinical trials, providing information for optimizing clinical trial design and guiding future application into clinical practice.

Original languageEnglish (US)
Pages (from-to)64-77
Number of pages14
JournalNeuro-oncology
Volume24
Issue number1
DOIs
StatePublished - Jan 5 2022

Keywords

  • drug distribution
  • drug response
  • mass spectrometry imaging
  • phosphoproteomics
  • t-CyCIF

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Multimodal platform for assessing drug distribution and response in clinical trials'. Together they form a unique fingerprint.

Cite this